Fennec Pharmaceuticals Inc. (FENC)
| Market Cap | 252.23M |
| Revenue (ttm) | 170,000 |
| Net Income (ttm) | -16.16M |
| Shares Out | 26.16M |
| EPS (ttm) | -0.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 96,546 |
| Open | 9.89 |
| Previous Close | 9.85 |
| Day's Range | 9.28 - 9.94 |
| 52-Week Range | 5.80 - 10.08 |
| Beta | -0.07 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+45.2%) |
| Earnings Date | Nov 15, 2021 |
About FENC
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product PEDMARK, a formulation of Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Trian...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FENC stock is "Strong Buy." The 12-month stock price forecast is 14.00, which is an increase of 45.23% from the latest price.
News
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
4 Breakout Stocks for Impressive Returns
SB, VTSI, FENC and APYX qualified the screen for breakout stocks for today.
Here's Why "Trend" Investors Would Love Betting on Adherex Technologies Inc. (FENC)
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why Momentum in Adherex Technologies Inc. (FENC) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adherex Technologies Inc. (FENC) could be a great choice. It is one of the several stocks that passed through our...
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique ...
Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circu...
Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility
RESEARCH TRIANGLE PARK, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique ...
Fennec Pharma Stock Is Trading Higher As Pedmark Is Under FDA Review For Chemo-Induced Toxicity
The FDA has accepted for review Fennec Pharmaceuticals Inc's (NASDAQ: FENC) resubmitted marketing application seeking approval for Pedmark (formulated sodium thiosulfate) to prevent ototoxicity induced ...
Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™
~ Prescription Drug User Fee Act (PDUFA) Target Action Date Set for November 27, 2021 ~
Fennec Pharma Refiles Pedmark US Application For Cisplatin-Induced Ototoxicity In Pediatric Patients
Fennec Pharmaceuticals Inc (NASDAQ: FENC) has resubmitted its marketing application to the FDA seeking approval for Pedmark (formulated sodium thiosulfate) for the prevention of ototoxicity (toxic to th...
Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™
~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ If Approved by the FDA, PEDMARK Stands to Be the First Therapy for t...
Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
~ Fennec Remains on Track to Finalize and Resubmit the New Drug Application for PEDMARK™ to the U.S. Food and Drug Administration in the Second Quarter of 2021 ~
Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update
~ Fennec is Working Closely with its Third-Party Drug Product Manufacturer to Finalize the New Drug Application (NDA) Resubmission for PEDMARK™ ~
Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
~ The Company Continues to Work with the FDA and Its Third-Party Drug Product Manufacturer to Fully Address CRL and Prepare NDA Resubmission for PEDMARK™ ~
FENC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 2, 2020 in the Class Action Filed on B...
New York, New York--(Newsfile Corp. - November 2, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Fennec Pharmaceuticals Inc. (NASDAQ: FENC...
FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Fennec Pharmaceuticals Inc. Investors of the Important ...
NEW YORK, Nov. 2, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. between February 11, 2020 and August 10, 202...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Fennec Pharmaceuticals Inc. of a Class Action Lawsu...
New York, New York--(Newsfile Corp. - November 2, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of F...
FENC Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and L...
New York, New York--(Newsfile Corp. - November 2, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" o...
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc...
Los Angeles, California--(Newsfile Corp. - November 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmace...
FENC Final Deadline Alert: Rosen, Top Ranked Global Counsel, Reminds Fennec Pharmaceuticals Inc. Investors of the Imp...
New York, New York--(Newsfile Corp. - October 30, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between Fe...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fennec Pha...
LOS ANGELES--(BUSINESS WIRE)---- $FENC #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 2, 2020 deadline to file a lead plaintiff motion in the class action file...
FENC Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC)...
DEADLINE MONDAY ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceutic...
Los Angeles, California--(Newsfile Corp. - October 30, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceu...
FENC CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files a Securities Fraud Class Action Lawsuit Against Fenn...
LOS ANGELES, Oct. 29, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Middle District of North Caroli...